iifl-logo

Syngene International Ltd Balance Sheet

652.55
(1.23%)
Sep 10, 2025|12:00:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

FINANCIALS

Y/e 31 Mar( In .Cr)Mar-2025Mar-2024Mar-2023Mar-2022

Equity Capital

402.5

402

401.4

400.8

Preference Capital

0

0

0

0

Reserves

4,236.4

3,789.5

3,217.5

2,891.2

Net Worth

4,638.9

4,191.5

3,618.9

3,292

Minority Interest

Debt

306.3

332.4

638.6

1,021.6

Deferred Tax Liability Net

119.2

128.5

122.1

125.2

Total Liabilities

5,064.4

4,652.4

4,379.6

4,438.8

Fixed Assets

3,121.3

3,077.5

2,386.1

2,739.2

Intangible Assets

Investments

1,468

927.6

940.8

1,034.4

Deferred Tax Asset Net

149.1

178.3

201.6

190.3

Networking Capital

-326.5

-59.2

341.8

-40.2

Inventories

150.3

234

332.8

179.4

Inventory Days

25.17

Sundry Debtors

469.4

427.5

484.4

508.2

Debtor Days

71.3

Other Current Assets

515.5

589.3

1,115.1

519.4

Sundry Creditors

-407.9

-310.2

-304.2

-344.9

Creditor Days

48.39

Other Current Liabilities

-1,053.8

-999.8

-1,286.3

-902.3

Cash

652.5

528.2

509.3

515.1

Total Assets

5,064.4

4,652.4

4,379.6

4,438.8

Syngene Intl. : related Articles

Syngene Gets FDA Nod on Biocon Park Inspection With VAI Status

The outcome of the inspection has been classified as “Voluntary Action Indicated” or VAI.

15 Jun 2025|09:00 PM
Read More
Syngene Reports ₹1,018 Crore Revenue in Q4 FY25

The purchase is anticipated to enhance Syngene's position in the biologics contract development and manufacturing organization (CDMO) arena, specifically in the US market.

24 Apr 2025|01:21 PM
Read More
Syngene International reports better than expected Q4 results

The company reported an operating EBITDA of ₹343.60 Crore in the quarter four of FY25. It registered a growth of 8.4% on a year-on-year basis.

24 Apr 2025|11:36 AM
Read More
Syngene Boosts Biologics Capacity with US Facility Acquisition

This acquisition will also augment Syngene’s biologics capabilities and further strengthen its global presence.

13 Mar 2025|01:40 PM
Read More
Syngene Reports 18% Profit Surge in Q3, Revenue Up 10.6%

The company's revenue from operations also grew healthily, up by 10.6% YoY to ₹943 crore, as against ₹853.5 crore in Q3 FY24.

24 Jan 2025|12:45 PM
Read More
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.